Darby Dental Supply has agreed to distribute GlaxoSmithKline (GSK) oral care products. Under the terms of the new distribution agreement, Darby is now an authorized distributor of GSK's full line of ...
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this ...
GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate ...
LONDON/MUMBAI (Reuters) - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being ...
TipRanks on MSN
AnaptysBio Files Legal Complaint Against GSK and Tesaro
AnaptysBio ( ($ANAB) ) has provided an update. On November 20, 2025, AnaptysBio filed a complaint in Delaware Chancery Court against TESARO, Inc.
GlaxoSmithKline (GSK) and Dentsply have entered into an agreement to create a portfolio of co-branded oral care products to be used in the dental office by patients suffering from tooth sensitivity.
It’s been an upbeat week for GSK as it reported a trio of positive updates stemming from vaccines and oncology products. Most notable, perhaps, was the news that the British drugmaker took a step ...
The new company, Haleon, launched with a market valuation of $36 billion. Behind the deal: GlaxoSmithKline move from Navy Yard was stealthy © 2025 American City ...
UK pharma major GSK has announced that the National Institute for Health and Care Excellence (NICE) has issued final guidance ...
TipRanks on MSN
GSK Expands Share Buyback Program with Latest Purchase
GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ...
BEIJING/LONDON (Reuters) -China has blocked GSK from participating in its bulk-buy drug procurement programme focused on off-patent medicines from Oct. 31 until April 29, 2024, over quality problems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results